Anti-Coagulants - Bhutan

Bhutan

The revenue in the Anti-Coagulants market in Bhutan is projected to reach US$190.90k by the year 2024.
It is expected to show an annual growth rate (CAGR 2024-2029) of 7.30%, resulting in a market volume of US$271.50k by 2029.
When compared globally, United States is expected to generate the highest revenue of US$16,740.00m in 2024.
Despite its small population and limited healthcare infrastructure, Bhutan has seen a growing demand for anti-coagulants, indicating an increasing awareness and treatment of cardiovascular diseases in the country.

Key regions: Australia, Japan, United States, Germany, Europe

Market

Region

Region comparison

Currency

Analyst Opinion

The Anti-Coagulants market in Bhutan has seen steady growth in recent years.

Customer preferences: Bhutan's population is aging, and as a result, there is an increasing demand for anti-coagulants. The prevalence of cardiovascular diseases and other chronic illnesses is also on the rise, leading to a greater need for anti-coagulant medications.

Trends in the market: The Anti-Coagulants market in Bhutan is growing due to the increasing prevalence of chronic diseases. There is also a growing awareness of the importance of preventative care, which has led to an increase in the use of anti-coagulants. In addition, the government of Bhutan has implemented policies to improve healthcare access and affordability, which has contributed to the growth of the market.

Local special circumstances: Bhutan is a small country with a population of less than a million people. The healthcare system is still developing, and there are limited resources available for healthcare services. This has led to challenges in accessing and delivering healthcare services, including the availability of anti-coagulants. However, the government has implemented policies to improve healthcare access and affordability, which has helped to address some of these challenges.

Underlying macroeconomic factors: Bhutan's economy is growing, but it is still largely dependent on agriculture and hydropower. The government has implemented policies to diversify the economy and promote private sector growth, which has led to increased investment in the healthcare sector. The growing demand for healthcare services, including anti-coagulants, has also contributed to the growth of the market. However, the limited resources available for healthcare services and the small size of the market may pose challenges for companies looking to enter the market.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.